Basic Daliresp Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In United States: Glucophage, Riomet, Fortamet
• ATC Code: A10BA02
• Forms & Dosages: Immediate-release tablets 250mg, 500mg, 850mg, 1000mg; Extended-release tablets 500mg, 750mg, 1000mg; Oral solution 500mg/5mL
• Manufacturers In United States: Merck, Teva, Sanofi, Bristol Laboratories, Sun Pharma, Hetero Labs (listed as global suppliers)
• Registration Status In United States: Approved by United States FDA (NDA/ANDA filings for metformin hydrochloride and extended-release)
• OTC / Rx Classification: Prescription Only (Rx) in nearly all countries

Everyday Use & Best Practices

Worried about when to take Daliresp and how it will fit into your day?

Morning Vs Evening Dosing

Daliresp (roflumilast 500 mcg) is taken once daily.

Many patients prefer evening dosing to lessen daytime nausea or gastrointestinal upset.

If side effects occur at night, move the dose to the morning and reassess with your clinician.

If you miss a dose, take it as soon as you remember unless the next dose is near — do not double up.

Taking With Or Without Meals

Roflumilast can be taken with or without food; consistency helps predict side effects.

If you notice stomach upset, take your tablet with a small snack or after a meal to reduce nausea.

Track timing against inhaled COPD medications so you maintain an easy routine and avoid missed doses.

Practical Tips

• Set a phone alarm for the same time each day to support once daily dosing adherence.
• Keep tablets in original packaging and confirm the imprint to ensure you have roflumilast tablets.
• Weigh weekly if you notice unexplained loss, and report changes to your provider.

Safety Priorities

Who needs to be careful before starting Daliresp?

Who Should Avoid It

Do not use Daliresp if you have severe liver impairment.

Tell your prescriber about current or recent depression, suicidal thoughts, significant unexplained weight loss, active alcohol misuse, or plans for pregnancy.

Always inform clinicians about all current medications, including over-the-counter and herbal products, to check for interactions.

Activities To Limit

Because Daliresp may cause dizziness, insomnia, or mood changes, be cautious driving or operating machinery until you know how it affects you.

Avoid heavy alcohol use because alcohol can worsen some side effects such as gastrointestinal upset and weight loss.

Monitor weight and mood closely and report significant changes immediately.

Checklist: Contraindications And Red-Flag Symptoms

• Severe hepatic impairment — do not start Daliresp.
• New or worsening depression, suicidal thoughts — seek immediate clinical review.
• Unexplained rapid weight loss or persistent nausea/vomiting — report promptly.
• Excessive alcohol use — discuss risks before using roflumilast.

Dosage & Adjustments

How is Daliresp usually prescribed and when might a dose change be needed?

General Regimen

The standard adult dose is roflumilast 500 mcg orally once daily (one tablet).

It is used as an add-on for patients with severe COPD with chronic bronchitis and frequent exacerbations despite bronchodilator therapy.

No routine titration is required; follow your prescriber’s instructions exactly.

Special Cases

No dose adjustment is usually needed for mild to moderate renal impairment.

Avoid use in severe hepatic impairment due to greater exposure and risk of adverse effects.

For elderly patients, start at the usual dose but monitor weight, liver tests, and mental health closely.

Dosing Quick-Reference

• Standard Adult Dose: roflumilast 500 mcg once daily.
• Renal Impairment: no routine adjustment for mild-moderate impairment.
• Hepatic Impairment: avoid use if severe.

User Testimonials

What do other people with COPD say after adding Daliresp?

Positive Reports

Many patients report fewer COPD exacerbations after Daliresp was added to inhaled therapy.

Some patients note fewer steroid or antibiotic courses and an overall improved quality of life.

Users often say sustaining bronchodilator use while adding roflumilast helped reduce emergency room visits.

Common Challenges

Frequent complaints include gastrointestinal side effects such as nausea and diarrhea, weight loss, insomnia, and mood changes early in therapy.

Some stop treatment because of persistent nausea or increased anxiety.

Patient Tips And Snippets

• “Taking it after dinner reduced my morning nausea.”
• “I kept a symptom diary and brought it to my follow-up to help my clinician decide.”
• “My ER visits decreased when roflumilast was added to my inhalers.”

Buying Guide

Where can you get Daliresp and how do you compare prices?

Pharmacy Sources

Daliresp (brand) and roflumilast generics are prescription-only medications in standard practice, and should be filled at major retail pharmacies, large chains, or credible online/mail-order pharmacies.

Ask a pharmacist about generic availability and interchangeability, and confirm you are receiving roflumilast 500 mcg tablets with the correct imprint.

Price Comparison

Cost varies by brand, insurance coverage, coupons, and manufacturer savings programs.

Compare retail, online, and mail-order prices, and check manufacturer copay cards if eligible.

If cost is a barrier, discuss patient assistance programs or alternative therapies with your prescriber.

Quick Verification Checklist For Pharmacies

• Confirm prescription authenticity and pharmacist license at the pharmacy.
• Verify the tablet is labeled roflumilast 500 mcg.
• Ask about generic roflumilast options to reduce cost.

Note: In our online pharmacy, daliresp is available without a prescription, with discreet delivery to United States in 5-14 days.

What’s Inside & How It Works

Curious what the tablet contains and how roflumilast helps COPD?

Ingredients Overview

The active ingredient is roflumilast 500 mcg per tablet.

Inactive ingredients vary by manufacturer, so check your package leaflet if you have allergies.

Always review the tablet imprint to confirm the correct product.

Mechanism Basics

Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation in the lungs.

By lowering airway inflammation, it reduces the risk of COPD exacerbations in patients with severe disease and chronic bronchitis.

Roflumilast is not a bronchodilator and must be used alongside inhaled long-acting bronchodilators for optimal control.

Mechanism-Of-Action Summary

• PDE4 inhibition → reduces inflammatory cell activity in the lungs.
• Less inflammation → fewer and less severe COPD exacerbations in selected patients.
• Used as an adjunct to bronchodilators, not as a replacement.

Main Indications

Who is roflumilast intended for, and are there off-label uses?

Approved Uses

Daliresp is indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

It is intended for use in addition to bronchodilator therapy when inhaled medications alone do not provide adequate control.

Off-Label Uses

Off-label or investigational uses have been discussed in research for other inflammatory lung conditions, but these are not standard practice.

Always discuss any non-approved uses thoroughly with your clinician before considering them.

Questions To Ask Your Prescriber

• Am I a good candidate for roflumilast given my exacerbation history?
• How will we monitor for side effects like weight loss or mood changes?
• What alternatives are appropriate if roflumilast is not tolerated?

Interaction Warnings

Which foods or medicines might change how Daliresp works?

Food Interactions

There are no major food interactions documented with roflumilast, but high alcohol intake can worsen side effects and is discouraged.

Keeping meal timing consistent can help manage gastrointestinal intolerance if it occurs.

Drug Conflicts

Roflumilast is metabolized via CYP3A4 and CYP1A2 pathways.

Strong CYP3A4 inducers such as rifampicin, phenytoin, and carbamazepine can lower roflumilast levels and reduce effectiveness.

Strong CYP3A4 inhibitors can increase roflumilast exposure and potentially increase side effects.

Drug-Interaction Checklist

• Provide a complete medication list, including OTC and herbal products, to your clinician.
• Flag strong CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine) before starting therapy.
• Discuss any antifungals, macrolide antibiotics, or protease inhibitors, which may affect CYP3A4 activity.

Latest Evidence & Insights

What do the trials and real-world use tell us about benefits and downsides?

Key Trial Takeaways

Clinical trials show roflumilast reduces moderate-to-severe COPD exacerbations in patients with the chronic bronchitis phenotype and a history of exacerbations when added to bronchodilators.

Benefits are greatest in patients with frequent exacerbations and chronic bronchitis symptoms.

Early side effects are common but often lessen over several weeks for those who can tolerate the therapy.

Real-World Considerations

Monitor for weight loss, psychiatric symptoms, and gastrointestinal intolerance during routine care.

Shared decision-making is important to weigh exacerbation reduction against tolerability, comorbidities, and polypharmacy.

Note: the supplied product-information in this file includes Real data for a different drug — INN: Metformin — which highlights that product datasheets can vary by drug; always confirm you are reading roflumilast-specific information when reviewing labels or datasheets.

Clinician-Patient Conversation Checklist

• Discuss expected timeframe for benefit and likely side effects.
• Agree on monitoring plan for weight, mood, and liver function.
• Plan follow-up within weeks of starting to reassess tolerability and benefit.

Alternative Choices

What else can help if Daliresp is not the right fit?

Other COPD Meds To Consider

Daliresp is an anti-inflammatory PDE4 inhibitor and not a bronchodilator.

Optimizing long-acting bronchodilator therapy such as LAMAs and LABAs and considering inhaled corticosteroids for appropriate phenotypes are primary alternatives.

Combination inhalers, pulmonary rehabilitation, smoking cessation, and vaccinations are essential components of COPD management.

When Daliresp May Not Be Best

If intolerable side effects, severe hepatic impairment, or psychiatric history predominate, clinicians may prefer optimizing bronchodilator therapy or considering other systemic options.

Never abruptly stop inhaled medications without clinician guidance.

If Daliresp Is Not Tolerated

• Reassess inhaler technique and adherence to LABA/LAMA therapy first.
• Consider switching to alternative inhaled combinations or pulmonary rehab referral.
• Discuss stopping roflumilast with your clinician if severe side effects occur.

Regulation Snapshot

What is roflumilast’s regulatory status and how do labels matter?

Approval & Classification

Daliresp (roflumilast) is prescription-only in the United States and many other countries.

It is approved as an adjunctive therapy to reduce COPD exacerbations in selected patients.

Keep prescriptions and safety communications up to date via FDA or other regulatory authority resources.

Label & Safety Communications

Read the official label for contraindications such as severe hepatic impairment and for any boxed warnings or safety updates.

NOTE: the supplied product-info in this file is for Metformin (INN: Metformin; ATC A10BA02), a different drug, which demonstrates that datasheets may be misfiled or mislabelled; always confirm you are consulting roflumilast-specific regulatory resources.

Label-Checking Table

• Confirm the active ingredient on the label is roflumilast 500 mcg.
• Use FDA or EMA product pages to view the current prescribing information and safety communications.
• If you encounter a Metformin datasheet when looking for roflumilast, stop and ask a pharmacist for the correct roflumilast label.

FAQ Section

What do patients ask most about daliresp?

Common Patient Questions

• Q: How quickly will I notice benefits? A: Exacerbation reduction is measured over months; some patients notice fewer flare-ups within 3–6 months.
• Q: Will it replace my inhaler? A: No — it is an add-on, not a bronchodilator.
• Q: Can I drink alcohol? A: Avoid heavy alcohol use because it may worsen side effects.

Troubleshooting

• If you experience severe GI upset, marked weight loss, or new/worsening mood symptoms, contact your provider immediately.
• Missed Dose Guidance: take when remembered unless the next dose is close; do not double up.
• If intolerable side effects occur, your clinician may stop treatment or reassess benefits versus risks.

Guidelines For Proper Use

How should patients be monitored before and during roflumilast therapy?

Routine Monitoring

Before starting, review liver function tests, psychiatric history, current medications that may interact, and baseline weight.

During treatment, monitor weight monthly early on, watch for gastrointestinal intolerance and mood changes, and reassess liver function if clinically indicated.

When To Stop Or Seek Help

Stop and call your clinician for suicidal thoughts, severe depression, severe abdominal pain with persistent nausea or vomiting, unexplained rapid weight loss, or signs of serious liver dysfunction such as jaundice or dark urine.

Keep emergency numbers handy and follow up promptly if red-flag symptoms appear.

Printable Checklist For Patients And Caregivers

• Pre-Start Screening: liver tests, psychiatric history, medication review.
• Ongoing: monthly weight checks for the first 3 months and routine mood screening.
• Stop-and-Call Triggers: suicidal ideation, severe GI symptoms, jaundice, rapid unexplained weight loss.

Delivery Across United States